These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31463596)

  • 1. Postoperative nonalcoholic fatty liver disease is correlated with malnutrition leading to an unpreferable clinical course for pancreatic cancer patients undergoing pancreaticoduodenectomy.
    Okabe H; Yamashita YI; Inoue R; Kinoshita S; Itoyama R; Yusa T; Nakao Y; Yamao T; Umezaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Hayashi H; Imai K; Chikamoto A; Baba H
    Surg Today; 2020 Feb; 50(2):193-199. PubMed ID: 31463596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of postoperative adjuvant chemotherapy on the development of nonalcoholic fatty liver disease after pancreatoduodenectomy.
    Nishikawa M; Aosasa S; Moriya T; Noro T; Hase K; Yamamoto J
    J Surg Res; 2016 Sep; 205(1):127-35. PubMed ID: 27621009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative Computed Tomography Assessments of the Pancreas Predict Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy.
    Ohgi K; Okamura Y; Yamamoto Y; Ashida R; Ito T; Sugiura T; Aramaki T; Uesaka K
    Medicine (Baltimore); 2016 Feb; 95(6):e2535. PubMed ID: 26871772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical impact of the remnant pancreatic volume and infectious complications on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Sato R; Kishiwada M; Kuriyama N; Azumi Y; Mizuno S; Usui M; Sakurai H; Tabata M; Yamada T; Isaji S
    J Hepatobiliary Pancreat Sci; 2014 Aug; 21(8):562-72. PubMed ID: 24824077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease after pancreatoduodenectomy is closely associated with postoperative pancreatic exocrine insufficiency.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sasaki H; Okano K; Sueda T
    J Surg Oncol; 2014 Nov; 110(6):720-6. PubMed ID: 24965234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system.
    Kato H; Isaji S; Azumi Y; Kishiwada M; Hamada T; Mizuno S; Usui M; Sakurai H; Tabata M
    J Hepatobiliary Pancreat Sci; 2010 May; 17(3):296-304. PubMed ID: 19809782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Nagai M; Sho M; Satoi S; Toyokawa H; Akahori T; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kinoshita S; Nishiwada S; Ikeda N; Kwon AH; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2014 Mar; 21(3):186-92. PubMed ID: 23798362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk factors of newly developed nonalcoholic fatty liver disease after pancreaticoduodenectomy].
    Yang YF; Cai ZH; Fu X; Zhang J; Qiu YD; Mao L
    Zhonghua Wai Ke Za Zhi; 2022 Jan; 60(1):46-51. PubMed ID: 34954946
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Yamazaki S; Takayama T; Higaki T; Moriguchi M; Yoshida N; Miyazaki T; Teshima Y
    J Gastroenterol; 2016 Jan; 51(1):55-62. PubMed ID: 25904096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated functional remnant pancreatic volume predicts nonalcoholic fatty liver disease after pancreaticoduodenectomy: use of computed tomography attenuation value of the pancreas.
    Maehira H; Iida H; Maekawa T; Yasukawa D; Mori H; Takebayashi K; Kaida S; Miyake T; Matsubara A; Tani M
    HPB (Oxford); 2021 May; 23(5):802-811. PubMed ID: 33046368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial.
    Yasukawa K; Shimizu A; Yokoyama T; Kubota K; Notake T; Seki H; Kobayashi A; Soejima Y
    J Am Coll Surg; 2020 Dec; 231(6):658-669. PubMed ID: 32927075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of pylorus preservation on the development of nonalcoholic fatty liver disease after pancreaticoduodenectomy: A historical cohort study.
    Jeon D; Park BH; Lee HC; Park Y; Lee W; Lee JH; Song KB; Hwang DW; Kim SC; Choi J
    J Hepatobiliary Pancreat Sci; 2022 Aug; 29(8):863-873. PubMed ID: 35434927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of predictive factors in patients with nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    Ito Y; Kenmochi T; Shibutani S; Egawa T; Hayashi S; Nagashima A; Kitagawa Y
    Am Surg; 2014 May; 80(5):500-4. PubMed ID: 24887731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy.
    Tanaka N; Horiuchi A; Yokoyama T; Kaneko G; Horigome N; Yamaura T; Nagaya T; Komatsu M; Sano K; Miyagawa S; Aoyama T; Tanaka E
    J Gastroenterol; 2011 Jun; 46(6):758-68. PubMed ID: 21267748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial.
    Satoi S; Sho M; Yanagimoto H; Yamamoto T; Akahori T; Kinoshita S; Nagai M; Hirooka S; Yamaki S; Nishiwada S; Ryota H; Ikeda N; Nakajima Y; Kon M
    J Hepatobiliary Pancreat Sci; 2016 Mar; 23(3):167-73. PubMed ID: 26748629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New onset non-alcoholic fatty liver disease after resection of pancreatic neuroendocrine tumors.
    Mackay TM; Genç CG; Takkenberg RB; Besselink MG; Somers I; Nieveen van Dijkum EJM
    J Surg Oncol; 2018 Jun; 117(7):1548-1555. PubMed ID: 29572825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors contributing to nonalcoholic fatty liver disease (NAFLD) and fat deposition after pancreaticoduodenectomy: A retrospective analysis.
    Izumi H; Yoshii H; Fujino R; Takeo S; Nomura E; Mukai M; Makuuchi H
    Ann Gastroenterol Surg; 2023 Sep; 7(5):793-799. PubMed ID: 37663962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreaticoduodenectomy is justified in a subset of elderly patients with pancreatic ductal adenocarcinoma: A population-based retrospective cohort study of 4,283 patients.
    Lu L; Zhang X; Tang G; Shang Y; Liu P; Wei Y; Gong P; Ma L
    Int J Surg; 2018 May; 53():262-268. PubMed ID: 29604352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe steatohepatitis with hepatic decompensation resulting from malnutrition after pancreaticoduodenectomy.
    Sim EH; Kwon JH; Kim SY; Jung SM; Maeng LS; Jang JW; Chung KW
    Clin Mol Hepatol; 2012 Dec; 18(4):404-10. PubMed ID: 23323257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
    Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
    Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.